Part of the UT Health Science Center
The Cancer Therapy & Research Center is the answer for cancer
A Cancer Center designated by the National Cancer Institute
A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination with Bevacizumab for Glioblastoma Following Bevacizumab Failure (CTRC#12-0105)
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
To enroll or if you have questions about participation
Type of Cancer Treated